Tackling reproducibility in academic preclinical drug discovery

被引：43

作者：

Frye, Stephen V. ^{[1
]}

Arkin, Michelle R. ^{[2
]}

Arrowsmith, Cheryl H. ^{[3
]}

Conn, P. Jeffrey ^{[4
]}

Glicksman, Marcie A. ^{[5
]}

Hull-Ryde, Emily A. ^{[1
]}

Slusher, Barbara S. ^{[6
]}

机构：

[1] Univ N Carolina, Eshelman Sch Pharm, Ctr Integrat Chem Biol & Drug Discovery, Chapel Hill, NC 27599 USA

[2] Univ Calif San Francisco, Sch Pharm, Small Mol Discovery Ctr, San Francisco, CA 94143 USA

[3] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada

[4] Vanderbilt Univ, Vanderbilt Ctr Neurosci Drug Discovery, Dept Pharmacol, Nashville, TN 37232 USA

[5] ORIG3N, Boston, MA 02210 USA

[6] Johns Hopkins Sch Med, Johns Hopkins Drug Discovery, Baltimore, MD 21205 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2015年 / 14卷 / 11期

关键词：

D O I：

10.1038/nrd4737

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.

引用

下载

页码：733 / 734

页数：2

共 50 条

[1] Tackling reproducibility in academic preclinical drug discovery
Stephen V. Frye
Michelle R. Arkin
Cheryl H. Arrowsmith
P. Jeffrey Conn
Marcie A. Glicksman
Emily A. Hull-Ryde
Barbara S. Slusher
Nature Reviews Drug Discovery, 2015, 14 : 733 - 734
[2] Tackling the reproducibility problem to empower translation of preclinical academic drug discovery: is there an answer?
Janero, David R.
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (06) : 595 - 600
[3] The reproducibility issue and preclinical academic drug discovery: educational and institutional initiatives fostering translation success
Janero, David R.
EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (09) : 835 - 842
[4] Mitigating risk in academic preclinical drug discovery
Dahlin, Jayme L.
Inglese, James
Walters, Michael A.
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (04) : 279 - 294
[5] Mitigating risk in academic preclinical drug discovery
Jayme L. Dahlin
James Inglese
Michael A. Walters
Nature Reviews Drug Discovery, 2015, 14 : 279 - 294
[6] Mean comparisons and power calculations to ensure reproducibility in preclinical drug discovery
Novick, Steven
Zhang, Tianhui
STATISTICS IN MEDICINE, 2021, 40 (06) : 1414 - 1428
[7] Machine learning in preclinical drug discovery
Catacutan, Denise B.
Alexander, Jeremie
Arnold, Autumn
Stokes, Jonathan M.
NATURE CHEMICAL BIOLOGY, 2024, 20 (08) : 960 - 973
[8] Preclinical techniques for drug discovery in psoriasis
Gujarathi, Pranjal P.
Korat, Rashmi H.
Gujarathi, Piyush S.
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
[9] Caenorhabditis elegans for preclinical drug discovery
Arya, Upasna
Das, Chinmaya Kumar
Subramaniam, Jamuna R.
CURRENT SCIENCE, 2010, 99 (12): : 1669 - 1680
[10] US academic drug discovery
Stephen Frye
Marina Crosby
Teresa Edwards
Rudolph Juliano
Nature Reviews Drug Discovery, 2011, 10 : 409 - 410

← 1 2 3 4 5 →